Letter by Ahmed et al Regarding Article, “Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
We read with great interest the recent article by Saito and colleagues.1 In their prospective observational cohort study after the conclusion of the Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes randomized controlled trial, they found that after a median 10-year follow-up, low-dose aspirin did not affect the risk for cardiovascular events or hemorrhagic stroke but was associated with an increased risk for gastrointestinal bleeding.
Use of aspirin in primary prevention is less clear in women compared with men. …